Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (38) ·
(none, never marketed) (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Lexotan (1) ·
Librium (1) ·
Lunesta (1) ·
Miltown (1) ·
Mogadon (1) ·
Nembutal (1) ·
Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Serax (1) ·
Sonata (1) ·
THIP (1) ·
Tranxene (1) ·
Versed (1) ·
Xanax (1) ·
Xyrem (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA modulator; glycine receptor agonist (1) ·
GABAA positive allosteric modulator (20) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Kavalactones; GABAA modulator; sigma receptor activity (1) ·
Melatonin receptor agonist (2) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Very potent 5-HT2A agonist; long duration (1)
uses:
None (65) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
preparations:
None (65) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
routes:
onset:
duration:
halflife:
None (63) ·
11-13 h (immediate-release); 11-16 h (extended-release) (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
Not well characterized (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
pregnancy:
None (63) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Category D'"`UNIQ--ref-0000006C-QINU`"' (1) ·
Not established (1)
Showing below up to 68 results in range #1 to #68.